Xeljanz (tofacitinib) Letter of Medical Necessity
Xeljanz (tofacitinib) carries a JAK class boxed warning stemming from the ORAL Surveillance trial, leading to stringent prior authorization criteria that mandate documentation of cardiovascular risk, malignancy history, and prior TNF inhibitor failure.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● psoriatic arthritis
- ● ulcerative colitis
- ● ankylosing spondylitis
- ● polyarticular course juvenile idiopathic arthritis
Why Xeljanz Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Black box warning criteria not addressed (age ≥50, CV risk, malignancy history)
- 2. TNF inhibitor not tried first (step therapy)
- 3. Lab monitoring not documented (CBC, LFTs, lipids)
- 4. Severity scoring or disease activity measures missing
What to Include in a Xeljanz Letter of Medical Necessity
Document age, cardiovascular risk profile, smoking status, malignancy history, prior TNF inhibitor trials with documented inadequate response or intolerance, baseline labs (CBC with differential, LFTs, lipid panel), disease activity scores (DAS28, CDAI for RA; partial Mayo for UC), and the clinical rationale for oral JAK inhibition over injectable alternatives.
Key clinical evidence to cite:
- ✓ ORAL Scan, ORAL Solo, ORAL Standard, ORAL Strategy, ORAL Surveillance trials
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines (post-Oral Surveillance update)
- 📖 AGA 2020 UC Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
Payers Covering Xeljanz
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Xeljanz Prior Authorization FAQ
Why was my Xeljanz prior authorization denied?
The most common denial reasons for Xeljanz are: Black box warning criteria not addressed (age ≥50, CV risk, malignancy history); TNF inhibitor not tried first (step therapy); Lab monitoring not documented (CBC, LFTs, lipids); Severity scoring or disease activity measures missing.
What should a Xeljanz Letter of Medical Necessity include?
Document age, cardiovascular risk profile, smoking status, malignancy history, prior TNF inhibitor trials with documented inadequate response or intolerance, baseline labs (CBC with differential, LFTs, lipid panel), disease activity scores (DAS28, CDAI for RA; partial Mayo for UC), and the clinical rationale for oral JAK inhibition over injectable alternatives.
Which payers cover Xeljanz?
Xeljanz is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.